Alimera Sciences Appoints David Dyer, MD, as Chief Retina Specialist

Alimera Sciences has announced the expansion of its leadership team with the appointment of David Dyer, MD, as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri.

“I am very excited that Dr. Dyer is joining our team in this newly created position as he brings the insights of a seasoned practicing retina specialist, and accomplished business owner to Alimera,” Rick Eiswirth, Alimera’s President and Chief Executive Officer, said in a company news release. “Dr. Dyer’s intricate retina knowledge, his years of practice experience, and his understanding of novel technologies will play an instrumental role in achieving our vision of being the place to be in retina, focused solely on the needs of retina specialists and their patients.”

“The opportunity to work with the Alimera team to develop the corporate vision into a reality and emphasize Iluvien’s ability to provide long-term control of recurrence of disease brings continued significant potential in both the U.S. and international markets,” said Dr. Dyer. “Additionally, the phase 4 NEW DAY Study is an exciting and needed comparison of long- term steroid versus anti-VEGF treatment. The company continues to grow its international footprint, creating a platform for potential future products.”